How does the dual therapy combination of Dolutegravir and Lamivudine (Spegra) compare to traditional triple ART regimens in terms of resistance development?
What factors contribute to Dolutegravir’s high genetic barrier to resistance?
I would appreciate evidence-based explanations, particularly referencing resistance mechanisms, pharmacodynamics, and relevant clinical trial data.
Hi
. I need to note that we are not medical professionals and, for your protection, cannot offer medical advice. As noted from our About Us page, "At H-I-V.net, we empower people living with this chronic health condition and caregivers to take control of HIV by providing a platform to learn, educate, and connect with peers and healthcare professionals:" https://h-i-v.net/about-us?_sp=1ce1736a-85b8-46a5-81c6-df0a82951003.1770949311793.
I can tell you that Spegra is a generic drug produced in India and not approved by the FDA. If you would like additional, specific information on the drug you would need to speak to a medical professional. Best, Richard (Team Member)
The medicine dolutegravir helps stop HIV from multiplying. It works even if the virus changes or becomes resistant because it sticks tightly to its key parts. It also stays active in your body for a long time, which helps keep the virus under control. According to studies, dolutegravir is an effective HIV treatment that rarely develops drug resistance.
